Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent (NCT07524439)
๐ฉบ Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine whether adding a ฮฒ-glucan moisturizing cream to routine skin care can enhance skin healing, accelerate visible recovery, reduce discomfort, and improve both patient and clinician experiences. The study will also learn about the safety and tolerability of the ฮฒ-glucan cream when used along with standard skin care. The main questions it aims to answer are: Are there visible changes in the severity of IAD when ฮฒ-glucan cream is added to standard care, and if so, to what extent does it reduce severity compared with standard care alone? Does the ฮฒ-glucan cream help IAD heal faster? Does the cream reduce symptoms such as pain, itching, tingling, or burning? What medical problems or side effects, if any, do participants experience while using the ฮฒ-glucan cream? Researchers will compare standard care plus ฮฒ-glucan cream to standard care alone to see if the ฮฒ-glucan cream provides additional benefit for treating IAD. Participants will: Receive either ฮฒ-glucan cream plus standard care or standard care alone Have the study cream applied once daily for up to 2 weeks Have their skin checked weekly by the study team using a standardized assessment tool Answer questions about symptoms such as pain, itching, tingling, and burning Allow photographs of the affected skin area to be taken for secure clinical review Be monitored for any side effects or skin reactions during the study
Who can join: Review the eligibility criteria below.
Location: University of Alberta Hospital โ Edmonton, Alberta
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of Alberta Hospital โ Edmonton, Alberta
๐ Contact the Study Coordinator
Phone: (780) 263-6245
Email: eatang@ualberta.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Fecal Incontinence
- Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury โ La Jolla, California
- Use of the LEVAยฎ Pelvic Health System for Fecal Incontinence โ Madison, Wisconsin
- Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence โ Richmond, Virginia
- Autologous Muscle Fiber Fragment Injections โ Winston-Salem, North Carolina
- Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury โ Cleveland, Ohio
- Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence โ Augusta, Georgia
Explore by condition: All Fecal Incontinence clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.